CPT2 and fatty liver disease: To evaluate the role of lysosomal lipolysis and/or mitochondrial oxidation in KCs for the attenuated hepatic steatosis phenotype, we generated and validated mice in which TFEB overexpression was combined with KC-specific Cpt2 knockout (KO; KCTfebCPT2fl/fl) to disrupt FAO or KC-specific Lipa KO (KCTfebLALfl/fl) to prevent lysosomal lipolysis (Supplemental Figure S5G, http://links.lww.com/HC9/C188).